Several other research firms have also recently commented on VYGR. BidaskClub raised Voyager Therapeutics from a hold rating to a buy rating in a research note on Saturday, August 25th. Morgan Stanley cut Voyager Therapeutics from an overweight rating to an equal rating in a research note on Monday, September 10th. BTIG Research reissued a buy rating and issued a $32.00 target price on shares of Voyager Therapeutics in a research note on Monday, September 10th. ValuEngine cut Voyager Therapeutics from a strong-buy rating to a buy rating in a research note on Monday, September 17th. Finally, Zacks Investment Research raised Voyager Therapeutics from a sell rating to a hold rating in a research note on Saturday, August 11th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the stock. The company has an average rating of Buy and an average price target of $26.56.
VYGR stock opened at $11.40 on Friday. The firm has a market cap of $371.15 million, a P/E ratio of -4.32 and a beta of 3.15. Voyager Therapeutics has a fifty-two week low of $10.90 and a fifty-two week high of $31.91.
In related news, Director James A. Geraghty purchased 3,000 shares of Voyager Therapeutics stock in a transaction dated Monday, September 10th. The shares were acquired at an average cost of $19.39 per share, for a total transaction of $58,170.00. Following the transaction, the director now directly owns 76,588 shares of the company’s stock, valued at $1,485,041.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Glenn Pierce purchased 5,000 shares of Voyager Therapeutics stock in a transaction dated Wednesday, September 12th. The stock was bought at an average price of $18.44 per share, for a total transaction of $92,200.00. The disclosure for this purchase can be found here. 33.60% of the stock is currently owned by company insiders.
Several large investors have recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in shares of Voyager Therapeutics by 10.5% in the 3rd quarter. Vanguard Group Inc. now owns 1,196,594 shares of the company’s stock worth $22,640,000 after purchasing an additional 113,442 shares during the last quarter. Standard Life Aberdeen plc bought a new position in shares of Voyager Therapeutics in the 3rd quarter worth $660,000. MetLife Investment Advisors LLC boosted its position in shares of Voyager Therapeutics by 69.5% in the 3rd quarter. MetLife Investment Advisors LLC now owns 18,050 shares of the company’s stock worth $342,000 after purchasing an additional 7,401 shares during the last quarter. Point72 Asset Management L.P. bought a new position in shares of Voyager Therapeutics in the 3rd quarter worth $1,929,000. Finally, Man Group plc bought a new position in shares of Voyager Therapeutics in the 3rd quarter worth $245,000. Institutional investors and hedge funds own 81.86% of the company’s stock.
Voyager Therapeutics Company Profile
Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease.
Further Reading: Futures Contract
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.